OMNITROPE 15 MG / 1.5 ML — DIN 02459647
SOMATROPIN : 15 MG / 1.5 ML · SANDOZ CANADA INCORPORATED · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is OMNITROPE?
OMNITROPE 15 MG / 1.5 ML contains SOMATROPIN : 15 MG / 1.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02459647, held by SANDOZ CANADA INCORPORATED, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 14-Aug-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is OMNITROPE used for?
Omnitrope (somatropin for injection) is indicated for: Children: The long-term treatment of children, who have growth failure due to an inadequate secretion of endogenous growth hormone (growth hormone deficiency [GHD]). Other causes of short stature should be excluded. SGA Indication: Omnitrope is indicated for the treatment of growth failure (current height standard deviation score [SDS] < -2) in short children born SGA (birth weight and/or length below -2 SD) and who fail to achieve catch-up growth (height velocity SDS < 0 during the last year) by 2 to 4 years or later. TS Indication: The treatment of short stature associated with Turner syndrome in patients whose epiphyses are not closed. ISS Indication: The long-term treatment of idiopathic short stature (ISS), also called non-growth hormone-deficient short stature, defined by height standard deviation score (SDS) < -2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, in pediatric patients for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other means. Omnitrope treatment for ISS should be prescribed only for those patients whose epiphyses are not closed. Adults: Omnitrope (somatropin [rDNA origin] for injection) is indicated for replacement of endogenous growth hormone in adults with growth hormone deficiency who meet either of the following two criteria: Adult Onset (AO): Patients who have growth hormone deficiency, either alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma; or Childhood Onset (CO): Patients who were growth hormone deficient during childhood as a result of congenital, genetic, acquired, or idiopathic causes. Patients who were treated with somatropin for growth hormone deficiency in childhood and whose epiphyses are closed should be re-evaluated before continuation of somatropin therapy at the reduced dose level recommended for growth hormone deficient adults. According to current standards, confirmation of the diagnosis of adult growth hormone deficiency in both groups involves an appropriate growth hormone provocative test with two exceptions: (1) patients with multiple other pituitary hormone deficiencies due to organic disease; and (2) patients with congenital/genetic growth hormone deficiency.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Somatropin cost around the world?
Somatropin is listed on 12 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 9 | 74 | AUD███.██ |
| Norway | max AUP (pharmacy retail) | 4 | 31 | NOK███.██ |
| Saudi Arabia | public | 22 | 25 | SAR███.██ |
| Luxembourg | reimbursement | 20 | 20 | EUR███.██ |
| Czechia | max producer price (ex-factory) | 5 | 19 | CZK███.██ |
| Austria | KVP (Kassenverkaufspreis) | 14 | 18 | EUR███.██ |
| Bahrain | retail (max) | 5 | 11 | BHD███.██ |
| Hungary | producer price (ex-factory) | 9 | 11 | HUF███.██ |
| Romania | max producer price | 10 | 11 | RON███.██ |
| Greece | producer price (ex-factory) | 10 | 10 | EUR███.██ |
| South Africa | single exit price | 7 | 8 | ZAR███.██ |
| United Arab Emirates | public | 3 | 3 | AED███.██ |
241 pack listings across 118 brand entries and 10 price bases, refreshed 08 Sep 2026. Ranges span every Somatropin pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Somatropin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
7 holders have a Canadian DIN containing Somatropin, across 49 DINs, of which 21 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PFIZER CANADA ULC | 13 | 12 | GENOTROPIN | Sourceable in Canada |
| EMD SERONO, A DIVISION OF EMD INC., CANADA | 8 | 5 | SAIZEN, SAIZEN 10IU - KIT, SAIZEN 8.8MG (5.83MG/ML), SEROSTIM | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 4 | 3 | OMNITROPE | Sourceable in Canada |
| NOVO NORDISK CANADA INC | 8 | 1 | NORDITROPIN FLEXPRO, NORDITROPIN NORDIFLEX, NORDITROPIN SIMPLEXX | Sourceable in Canada |
| ELI LILLY CANADA INC | 7 | 0 | HUMATROPE, HUMATROPE - 13.3MG, HUMATROPE - 26.6MG, HUMATROPE - 6.7MG | No marketed DIN |
| HOFFMANN-LA ROCHE LIMITED | 7 | 0 | NUTROPIN - KIT PWS(10MG) & LIQ(10ML) IM SC, NUTROPIN - KIT PWS(5MG) & LIQ(10ML) IM SC, NUTROPIN AQ - SC 5MG/ML, NUTROPIN AQ NUSPIN 10, NUTROPIN AQ NUSPIN 20, +2 more | No marketed DIN |
| NOVOPHARM LIMITED | 2 | 0 | BIO-TROPIN | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 15 MG / 1.5 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS |
| Pack configuration (monograph) | Omnitrope 5.0 mg/1.5 mL is supplied in the following pack sizes: • One cartridge per carton • Five cartridges per carton • Ten cartridges per carton Omnitrope 10.0 mg/1.5 mL is supplied in the following pack sizes: • One cartridge per carton • Five cartridges per carton • Ten cartridges per carton Omnitrope 15.0 mg/1.5 mL is supplied in the following pack sizes: • One cartridge per carton • Five cartridges per carton |
| Storage | After the first injection, the content of the cartridge must be used within 28 days. The cartridge should remain in the pen and be refrigerated between 2 and 8°C. Do not freeze. Protect from light |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Somatropin |
|---|---|
| ATC code | H01AC01 |
| AHFS class | 68:28.00 |
| Biosimilar biologic | Yes |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02459647 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2459647 |
| Brand name | OMNITROPE |
| Generic / active ingredient | SOMATROPIN : 15 MG / 1.5 ML |
| Market authorization holder | SANDOZ CANADA INCORPORATED |
| Health Canada schedule | Prescription |
| ATC code | H01AC01 |
| ATC anatomical main group | H — Systemic hormonal preparations |
| ATC therapeutic subgroup | H01AC |
| Current status | MARKETED |
| Status date | 14-Aug-2017 |
| Original market date | 2017-08-14 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
21 of 49 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| GENOTROPIN | 1.2 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | 02401797 |
| GENOTROPIN | 1.4 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | 02401800 |
| GENOTROPIN | 0.8 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | 02401770 |
| GENOTROPIN | 0.6 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | 02401762 |
| GENOTROPIN | 1 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | 02401789 |
| GENOTROPIN | 0.2 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | 02401746 |
| GENOTROPIN | 12 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | 02401711 |
| GENOTROPIN | 0.4 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | 02401754 |
| GENOTROPIN | 5.3 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | 02401703 |
| GENOTROPIN | 1.6 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | 02401819 |
2 · Same class — other molecules in ATC H01AC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Somatropin | BIO-TROPIN · GENOTROPIN · HUMATROPE · HUMATROPE - 13.3MG · +17 more | 49 | 21 | Yes |
| Somapacitan | SOGROYA | 3 | 3 | Yes |
| Somatrogon | NGENLA | 2 | 2 | Yes |
| Mecasermin | INCRELEX | 1 | 1 | Yes |
| Somatrem | PROTROPIN - KIT IM SC 10MG/VIAL · PROTROPIN - KIT IM SC 5MG/VIAL · PROTROPIN INJ PWS 10MG/VIAL · PROTROPIN PWS 5MG/VIAL | 4 | 0 | Not in Canada |
| Tesamorelin | EGRIFTA | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC H01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| H01AX | Pegvisomant | 5 | 5 |
| H01AA | Corticotrophin · Tetracosactide | 4 | 1 |
| H01AB | Thyrotrophin Alfa | 1 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is OMNITROPE called?
The same molecule, Somatropin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Genotropin MiniQuick | Latin | Australia |
| Saizen | Latin | Australia, Czechia, Norway, Saudi Arabia |
| Norditropin FlexPro | Latin | Australia, Czechia, Norway, Saudi Arabia |
| Genotropin | Latin | Bahrain, Czechia, Norway |
| Genotropin GoQuick | Latin | Australia, Bahrain |
| Scitropin A | Latin | Australia |
| Humatrope | Latin | Czechia, South Africa |
| NORDITROPIN NORDIFLEX | Latin | Bahrain |
| SAIZEN SOLUTION FOR INJECTION | Latin | Bahrain |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.